Table 3.

Unadjusted and Adjusted Hazard Ratios for Herpes Zoster Comparing Individuals Who Received Recombinant Zoster Vaccine With and Without Concomitant Vaccine

Characteristic	Unadjusted HR (95% CI)	Adjusted HRa (95% CI)
Overall	0.67 (.47–.95)	0.75 (.53–1.08)
Age at index dateb
50–59 y	0.79 (.28–2.26)	0.74 (.25–2.21)
60–69 y	0.72 (.43–1.22)	0.82 (.48–1.40)
70–79 y	0.57 (.31–1.06)	0.61 (.33–1.14)
≥80 y	0.76 (.26–2.25)	0.86 (.28–2.58)
Sex
Female	0.66 (.44–1.01)	0.75 (.49–1.15)
Male	0.71 (.38–1.33)	0.82 (.43–1.55)
Race/Ethnicityc
Non-Hispanic White	0.76 (.49–1.16)	0.84 (.54–1.30)
Non-Hispanic Black	1.07 (.19–5.86)	3.57 (.26–48.24)
Hispanic	0.61 (.26–1.41)	0.70 (.29–1.66)
Non-Hispanic Asian	0.42 (.14–1.20)	0.45 (.15–1.33)

Abbreviations: CI, confidence interval; HR, hazard ratio.

Cox proportional hazards model for herpes zoster (HZ) comparing individuals who received recombinant zoster vaccine (RZV) with and without concomitant vaccine, adjusted for all other variables in Table 1.

The index date was the date of the second RZV dose.

There were no HZ events among individuals of other race/ethnicity who received RZV with concomitant vaccine.